Pioneering next-generation diagnostics for safer pregnancies.
Lepzi has been awarded a grant to advance development of next-generation PLGF and sFlt-1 tests to aid in the diagnosis of preeclampsia
Lepzi is pleased to announce that it has been awarded a grant from Gates Foundation to further develop its PLGF and sFlt-1 point-of-care tests to aid in the diagnosis of pregnant women at risk of preeclampsia.
Preeclampsia is a major cause of maternal deaths, neonatal deaths, and premature births worldwide. The rates are particularly high in low- and middle-income countries (LMICs), where access to reliable diagnostics is often limited. Lepzi remains committed to making the diagnosis of preeclampsia as simple and accessible as possible, even in challenging healthcare environments.
The Lepzi® PLGF Test, a true point-of-care assay using whole blood, has already shown excellent results in clinical studies conducted in the UK and Africa, as published in peer-reviewed journals. The test is currently being evaluated within a broader international program — the PAPAGAIO Study — spanning five countries.
Lepzi also maintains a strong focus on continuous cost optimisation, aiming to make advanced maternal diagnostic tools available to as many women as possible.
Through this new grant, the foundation will support Lepzi in developing an improved dual-biomarker test (PLGF + sFlt-1) designed to work with finger-prick blood samples. The project will also include a next-generation reader that is:
The initiative marks another step forward in Lepzi’s mission to deliver accurate, affordable, and accessible diagnostics for preeclampsia across diverse healthcare systems.
The project will commence in October 2025 and is expected to be completed by March 2027.
About Lepzi
Lepzi is a diagnostics innovation company specialising in point-of-care solutions for maternal and oncology applications. The company operates globally with R&D activities in Europe, North America, and Asia, combining technological innovation with clinical partnerships to improve access to essential diagnostics worldwide.
For more information, visit www.lepzi.com